首页>
外文期刊>The international journal of neuropsychopharmacology
>A Study in First-Episode Psychosis Patients: Does Angiotensin I-Converting Enzyme Activity Associated With Genotype Predict Symptom Severity Reductions After Treatment With Atypical Antipsychotic Risperidone?
【24h】
A Study in First-Episode Psychosis Patients: Does Angiotensin I-Converting Enzyme Activity Associated With Genotype Predict Symptom Severity Reductions After Treatment With Atypical Antipsychotic Risperidone?
Background Our previous studies showed increased angiotensin I-converting enzyme (ACE) activity in chronic schizophrenia patients compared with healthy control (HC) volunteers, and the relevance of combining ACE genotype and activity for predicting schizophrenia was suggested. Methods ACE activity was measured in plasma of ACE insertion/deletion (I/D) genotyped HC volunteers (n?=?53) and antipsychotic-na?ve first-episode psychosis (FEP) patients (n?=?45) assessed at baseline (FEB-B) and also after 2 months (FEP-2M) of treatment with the atypical antipsychotic risperidone. Results ACE activity measurements showed significant differences among HC, FEP-B, and FEP-2M groups (F?=?5.356, df?=?2, P =?.005) as well as between HC and FEP-2M (post-hoc Tukey’s multiple comparisons test, P =?.004). No correlation was observed for ACE activity increases and symptom severity reductions in FEP as assessed by total Positive and Negative Syndrome Scale (r?=??0.131, P =?.434). FEP subgrouped by ACE I/D genotype showed significant ACE activity increases, mainly in the DD genotype subgroup. No correlation between ACE activity and age was observed in FEP or HC groups separately (r?=?0.210, P =?.392), but ACE activity level differences observed between these groups were influenced by age. Conclusions The importance of measuring the ACE activity in blood plasma, associated with ACE I/D genotyping to support the follow-up of FEP patients, did not show correlation with general symptom amelioration in the present study. However, new insights into the influence of age and I/D genotype for ACE activity changes in FEP individuals upon treatment was demonstrated.
展开▼
机译：背景技术我们之前的研究表明，与健康对照（HC）志愿者相比，慢性精神分裂症患者中的血管紧张素I-转换酶（ACE）活性增加，并提出了组合ACE基因型和活性来预测精神分裂症的相关性。方法在ACE插入/缺失（I / D）基因分型HC志愿者的血浆中测量ACE活性（n？=β53）和抗精神病药症（FEP）患者（N？=？45）评估基线（2月B）和2个月（FEP-2M）治疗与非典型抗精神病药酮的治疗。结果ACE活性测量显示HC，FEP-B和FEP-2M组之间的显着差异（f？=Δ5.356，df？=Δ2，p =α.005）以及HC和FEP-2M之间（后 - hoc tukey的多重比较测试，p = 004）。对于ACE活性没有任何相关性，通过总阳性和阴性综合征尺度评估（R？= 0.131，P = 434）评估，因此FEP中的增长和症状严重程度降低。通过ACE I / D基因型的FEP亚组显示出显着的ACE活性，主要是在DD基因型亚组中。在FEP或HC组中不观察到ACE活性和年龄之间的相关性（R？= 0.210，P = 392），但这些组之间观察到的ACE活性水平差异受年龄的影响。结论测量与ACE I / D基因分型相关的血浆中ACE活动的重要性，以支持FEP患者的随访，并未表现出与本研究中的一般症状改善的相关性。然而，证明了对治疗后FEP个体的ACE活性变化的年龄和I / D基因型的新见解。
展开▼
